Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25968241 | 0.84 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL26787436 | 0.81 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL22381973 | 0.80 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL25968172 | 0.80 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL22968403 | 0.76 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL22968404 | 0.75 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL6365760 | 0.74 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL25966410 | 0.73 | KDM4E (0.55) | KDM4ETAS1R3TAS1R1MEN1KMT2A | |
| SCHEMBL16368460 | 0.73 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL31677373 | 0.71 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | KDM4E 1564/4885TAS1R3 2186/4885TAS1R1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.